Journal
NEUROSCIENTIST
Volume 29, Issue 1, Pages 78-96Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/10738584211016409
Keywords
Alzheimer's disease; natural peptides; nanotechnology; animal venoms; amyloid-beta; novel treatments
Categories
Ask authors/readers for more resources
This review discusses the etiology, current treatment options, and new developments in the field of Alzheimer's disease. While there are limited treatment options available, new peptide-based treatments show promise, and nanotechnological strategies may help overcome existing limitations.
Alzheimer's disease (AD) is the main cause of dementia in the world and its etiology is not yet fully understood. The pathology of AD is primarily characterized by intracellular neurofibrillary tangles and extracellular amyloid-beta plaques. Unfortunately, few treatment options are available, and most treat symptoms, as is the case of acetylcholinesterase inhibitors (IAChE) and N-methyl-d-aspartate receptor antagonists. For more than 20 years pharmaceutical research has targeted the amyloid cascade hypothesis, but this has not produced meaningful results, leading researchers to focus now on other characteristics of the disease and on multitarget approaches. This review aims to evaluate some new treatments that are being developed and studied. Among these are new treatments based on peptides, which have high selectivity and low toxicity; however, these compounds have a short half-life and encounter challenges when crossing the blood-brain barrier. The present review discusses up-and-coming peptides tested as treatments and explores some nanotechnological strategies to overcome the downsides. These compounds are promising, as they not only act on the symptoms but also aim to prevent progressive neuronal loss.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available